Customize your JAMA Network experience by selecting one or more topics from the list below.
To conduct a cost-effectiveness analysis of anesthetic agents to reduce the pain of peripheral intravenous cannulation in an emergency department (ED) setting.
Cost-effectiveness analysis in which costs were measured as the cost of the agent plus costs associated with time in the ED using data from our hospital cost accounting system. Outcomes were measured as improvements in the self-reported visual analog scale (VAS) pain scores. Variables considered unique to the various agents were cost of the agent, time to peak onset, success rates of cannulation, and mean reduction in VAS scores.
A cohort of patients aged 3 through 18 years enrolled in randomized controlled trials that compared analgesic modalities to facilitate peripheral intravenous cannulation was identified through medical databases searched from their inception (earliest year, 1966) through June 2007.
Main Outcome Measures
The main outcome measure was the incremental cost-effectiveness ratio, which represented the additional cost that must be incurred by the hospital to obtain a reduction of 1 additional unit (10 mm or 1 cm) in the VAS score compared with a baseline option of no anesthetic.
Our results suggest that the needle-free jet injection of lidocaine device had the lowest incremental cost-effectiveness ratio, followed by intradermal injection of buffered lidocaine; lidocaine iontophoresis; nitrous oxide inhalation analgesia; a heated lidocaine and tetracaine patch; sonophoresis with lidocaine cream, 4%; lidocaine cream alone, 4%; and use of a eutectic mixture of lidocaine and prilocaine cream.
Currently, the needle-free jet injection of lidocaine device and injection of buffered lidocaine appear to provide the most cost-effective alternatives to pediatric ED physicians.
It is well known that even minor and frequently performed procedures, such as peripheral intravenous (PIV) cannulation, invoke significant pain in children and increase fear and anxiety in children and their caregivers.1-3 During the last decade, several anesthetics have been investigated in clinical trials to explore the best options for amelioration of low to moderate pain associated with needlesticks in children.4-6 Consequently, pediatric emergency care physicians have several modalities to select from, each with varying time to onset, acquisition cost, and success rates. We are not aware of any prior comparative pharmacoeconomic analysis of pain management practices during PIV cannulation in the pediatric emergency department (ED) setting.
Our primary objective was to conduct a cost-effectiveness analysis that compared costs and outcomes associated with anesthetic agents during pediatric PIV cannulation. Costs were measured as the cost of the agent plus costs associated with time in the ED. Outcomes were measured as improvements (decreases) in self-reported visual analog scale (VAS) pain scores. A decision analytic model was constructed using relevant probabilities of success and outcomes from published studies of pediatric patients who underwent PIV cannulation aided by analgesia.
Types of studies
For this decision analysis, we included randomized controlled trials that involved use of analgesics for relief of needlestick pain. Unpublished data and results from phase 3 trials that were not subject to peer review were excluded.
Types of participants
We included trials that involved children and youth between the ages of 3 and 18 years, of all ethnic origins, of both sexes, and regardless of the reason for the needlestick procedure (ie, chronic vs acute condition).
Types of intervention
We included trials that compared the efficacy of topical and/or inhalation (nitrous oxide) analgesic modalities. These trials may have included a placebo comparison, a no treatment control, or a comparison of other topical anesthetics. We restricted trials to those that involved peripheral intravenous cannulation only because, based on clinical experience, pain associated with venipuncture is not equivalent to that experienced during intravenous cannulation in children. For studies that fulfilled the initial review criteria, full-text articles were obtained and assessed for possible inclusion. To be included, studies were required to be randomized controlled trials.
Types of outcome measures
Self-reported measure of pain and ease of cannulation (success rate with first attempt) were the primary outcomes for this decision analysis. The studies we reviewed also contained other outcomes measures, such as skin changes or other adverse reactions, including anxiety that precluded child participation, time from onset of application to effective anesthesia and duration of anesthetic effect, and cost and acceptability of the analgesic agent to the child, parent, or physician measured by self-report.
Search methods of identification of studies
A combination of medical subject heading (MeSH) and free-text search terms was used to search the literature databases for possible articles. The following MeSH terms (uppercased) and free-text terms (lowercased) were used: (1) ANESTHETICS, LOCAL; (2) PHLEBOTOMY; (3) ANESTHETICS, LOCAL and PHLEBOTOMY; (4) CATHETERIZATION, PERIPHERAL; (5) intravenous and peripheral; (6) ANESTHETICS, LOCAL and CATHETERIZATION, PERIPHERAL; and (7) nitrous oxide and venous cannulation.
In addition to computer-assisted literature searches, we identified other eligible literature through the manual review of identified reports and reference lists, focusing especially on review articles to identify additional relevant references. We also used articles and other items on the topic that we had been collecting since 2003 through regular review of the literature on pediatric pain management, professional interactions (eg, conferences), and ad hoc literature searches. Our search was restricted to English-language articles. Based on our experience and the preoperative literature, nitrous oxide inhalation analgesia is a useful adjunct to facilitate PIV cannula placement with or without topical anesthetic. It is ideally suited for the older anxious child (aged >5-6 years) who is mature enough to breathe through the nasal hood.
The following databases were searched: Cochrane Database of Systematic Reviews (1993 to June 2007), MEDLINE (1966 to June 2007), PubMed (1966 to June 2005), EMBASE (1988 to June 2007), Clinicaltrials.gov (2002 to June 2007), and EBM Reviews (1991 to June 2006).
Using the search strategy, we identified 113 unique references. Fifty-eight studies fulfilled the review criteria. Forty-two were excluded for 1 or more reasons. Nineteen trials included adult participants. In 3 studies7-9 that investigated vapocoolant sprays, the intervention was not superior to placebo (ie, lacked efficacy). Nine studies10-18 involved a topical anesthetic (amethocaine gel or tetracaine) that was not available in the United States. In 4 studies,18-21 the intervention was venipuncture without venous cannulation. Four studies22-25 used a measurement tool other than the self-reported VAS. Two studies26,27 included patients who were younger than 3 years. One study28 was published as an abstract only. Seventeen trials29-45 that enrolled 1287 children were included in the decision analysis model.
The primary clinical outcome for this decision analysis was pain during intravenous cannulation. Because pain is a subjective experience, self-report is considered the criterion standard for measuring levels and changes in pain.46 We chose to use the self-reported VAS measurement of pain because this scale has had extensive use in the measurement of pain in adult and pediatric patients and has been reported as a reliable and valid measure of pain intensity, with accuracy in assessing changes in pain perception over time.46-51
The minimum clinically important change for a VAS score is considered to range from 9 to 18 mm.52-56 We included trials with the child's self-report of pain because parent's or health care professional's assessment of pain in the child has been shown to be inaccurate.57,58
We also considered the pain of actual drug provision in our model. Lidocaine iontophoresis is associated with significant discomfort and pain during application. The cumulative failure rate from the literature, due to inability to tolerate iontophoresis, was 6.9%.33,36,44,45 This intolerability rate was included in our model. Lander et al39 reported the mean (SD) pain score of dressing removal after application of a eutectic mixture of lidocaine and prilocaine cream (EMLA) in children to be 14.3 (20.7) mm on the VAS. Remaining consistent with our overall assumption that payoffs are additive, the pain of bandage removal was added to the overall pain score associated with EMLA. Data are conflicting on pain reported during application of the needle-free jet injection of lidocaine (NJILD) device from studies that involved adult participants.59,60 However, a randomized, controlled, comparative trial35 suggests that the jet injection device was not painful and was well tolerated by pediatric patients, with 84% of patients reporting no pain at application compared with 61% in the EMLA group at the time of dressing removal. Based on recent data on the use of laser preparation of the skin, the median pain of laser application was reported to be 0.28 Therefore, with respect to the pain associated with activation of NJILD or use of laser or sonophoresis, because the child does not have an opportunity to reject these methods, we assumed that the global self-reported VAS score would incorporate the discomfort associated with these methods.
Eight methods for decreasing pain and distress associated with needlesticks were included in the decision analysis. Table 1 summarizes the probabilities used in the analysis. When multiple studies reported VAS scores using the same agent, weighted means (based on the number of patients receiving the particular agent in the study) were calculated.
Costs were measured as the cost of the agent plus costs associated with patient time in the ED. Unit costs for each of the agents were obtained from Le Bonheur Children's Medical Center's cost accounting system or through price quotes from vendors (for agents not currently in use at Methodist Le Bonheur Health Care). These prices represent the hospital's actual acquisition costs. Because the equipment and nitrous oxide gas is piped into the walls for use in the ED at Le Bonheur Children's Medical Center, the unit cost for nitrous oxide was included in the fixed ED cost. Similarly, in accordance with our hospital's cost accounting system, the cost of needles and syringes associated with use of injectable buffered lidocaine was also included in the fixed cost of supplies required to maintain a full-service ED. Furthermore, it is usual practice at our institution that once the 5-g tube of EMLA or lidocaine, 4%, is dispensed, it is charged to the patient regardless of the volume used.
Because we could not obtain consistent information on mean PIV cannulation times for pediatric ED patients, we conducted a prospective cohort study of a convenience sample of 25 patients in our own ED to determine these mean times. Overhead cost data from our hospital were used to estimate cost of patient time in the ED. Specifically, the costs of maintaining a full-service ED open 24 hours 7 days per week were converted to cost per ED room per hour. These costs included direct fixed costs (plant operations, biomedical instrumentation costs, and environmental services) and variable ED costs (salaries, benefits, and supplies) attributable to the ED by the hospital's cost accounting system. Table 2 summarizes the cost data used in our analyses.
Probabilities of cannulation success, pain outcomes, and cost data were combined to construct a decision analytic model that compared the cost-effectiveness of the 8 anesthetic agents for facilitating PIV cannulation in children. Tree Age Data 3.5 software (Tree Age Software Inc, Williamstown, Massachusetts) was used for decision analysis. Sensitivity analyses were used to vary the probabilities and costs from the no anesthetic option to assess the stability of the preferred strategy. Probabilities and costs were varied across the range of values given in Table 2. The variables of interest were those with relative uncertainty: time to start a PIV cannulation on first (5-30 minutes) and second (5-13 minutes) attempts, success rate of PIV cannulation (72%-100%), and cost of the agents and fixed ED costs. The University of Tennessee Health Sciences Center institutional review board approved this study.
Figure 1 provides a summary of the decision tree, and Table 3 provides a summary of the various anesthetic strategies, costs, and outcomes relative to no anesthetic and the resulting incremental cost-effectiveness ratios (ICERs). In our study, the ICER represents the additional cost that must be incurred by the hospital to obtain a reduction of 1 additional unit (10 mm or 1 cm) in the VAS score compared with a baseline option of no anesthetic. Our results suggest that based on currently available data on outcomes and costs, the NJILD has the best ICER.
Decision analysis tree showing the 8 treatment options for analgesia during peripheral intravenous (PIV) cannulation. The patient may or may not have his or her intravenous cannula initiated at first attempt, which relates to the probability of successful intravenous cannula insertion with each modality. These probabilities and estimates of their costs are given in Table 1 and Table 2. The payoff node represents the additional cost associated with use of anesthetic compared with the routine practice of using no anesthetic and the improvement in visual analog scale (VAS) pain scores with use of analgesia. EMLA indicates a eutectic mixture of lidocaine and prilocaine cream; NJILD, needle-free jet injection of lidocaine; PIV2, second attempt at insertion of PIV cannula after failed initial attempt; and US, ultrasonography.
We conducted a number of 1-way sensitivity analyses to examine the robustness of our results to changes in key variables. Specifically, we explored the impact of changing: ED room costs per hour (range, $15-$64), the success rates of cannulation (range, 72%-100%), and the average time to initiate a PIV cannulation (range, 5-20 minutes). These ranges were selected based on ranges published in the literature (if available) or plausible extreme values based on internal data (Figures 2, 3, and 4).
Report of results of sensitivity analysis to a change in the variable fixed cost per emergency department (ED) room per hour. A, Fixed cost of the ED room was $15; B, fixed cost of the ED room was $39.50; and C, fixed cost of the ED room was $64. EMLA indicates a eutectic mixture of lidocaine and prilocaine cream; NJILD, needle-free jet injection of lidocaine.
Report of results of sensitivity analysis to a change in the variable probability of peripheral intravenous cannulation success without anesthesia. A, Probability of peripheral intravenous cannulation success without anesthesia was 0.72; B, probability of peripheral intravenous cannulation success without anesthesia was 0.86; and C, probability of peripheral intravenous cannulation success without anesthesia was 1.00. EMLA indicates a eutectic mixture of lidocaine and prilocaine cream; NJILD, needle-free jet injection of lidocaine.
Report of results of sensitivity analysis to a change in the variable average time for a nurse to insert a peripheral intravenous (PIV) cannula, including set-up time. A, Average time to insert PIV cannula was 0.08 hour; B, average time to insert PIV cannula was 0.29 hour; and C, average time to insert PIV cannula was 0.50 hour. EMLA indicates a eutectic mixture of lidocaine and prilocaine cream; NJILD, needle-free jet injection of lidocaine.
Graphic representation of sensitivity analysis involves the creation of multiple graphs, each corresponding to a single value in the range of possible values in the sensitivity analysis. In Figure 2, we see that 3 options (buffered lidocaine, NJILD, and iontophoresis) create the “cost-effective frontier”; these modalities represent the 3 best available options because they represent the highest reduction in pain scores possible for the money spent. Buffered lidocaine represents the least costly option (ie, for a minimal expense, ED physicians are able to reduce pain modestly). The NJILD represents the most cost-effective option (ie, for a modest increment in cost, pain can be substantially reduced). If the institution is willing to spend more, they may want to consider iontophoresis as the highest cost option along this cost-effective frontier. All of the other options on the graph are dominated (ie, there is always a better choice that offers more pain relief for the same money or the same pain relief for less money).
Similarly, we prepared a series of graphs to explore the impact of changing cannulation success rates in the range of 72% to 100% (and the average time to initiate a PIV cannulation in the range of 5 to 20 minutes). These analyses revealed that, in a range of plausible scenarios, the use of NJILD remained the preferred strategy.
To the extent that ED personnel can anticipate the need for analgesia, they can minimize wait time by application of EMLA, lidocaine, or the lidocaine-tetracaine patch in triage. A sensitivity analysis that provides the range of costs that might be expected in this scenario was conducted. The relative ICERs with the assumption that wait time after application of these 3 modalities is 0 are given in Table 4.
One anesthetic agent that did not make it into our model was laser-assisted anesthesia because currently available data come from studies that include extremely young children (aged <3 years) or those not yet published in peer-reviewed journals (abstract).27,28 To assess the effect on our model of including these data, we conducted a separate decision analysis, including the additional anesthetic option and VAS scores reported by these researchers. In this model, laser-assisted anesthesia yielded an ICER of 20.06 relative to the no anesthetic option and was dominated by the 3 preferred strategies: NJILD, buffered lidocaine, and lidocaine iontophoresis.
Because it is possible that a young child may not allow injection of buffered lidocaine, we conducted a sensitivity analysis for the intolerability of buffered lidocaine. Even if this rate were as high as 6.9%, as reported for lidocaine iontophoresis, buffered lidocaine injection would still dominate iontophoresis, albeit with a lower ICER of 2.53.
Given the paucity of pediatric literature on the use of NJILD, sonophoresis, and the lidocaine-tetracaine patch, the possibility of bias exists in favor of these relatively less investigated modalities. We, therefore, performed a final sensitivity analysis assuming uniform reduction in pain scores across all modalities, thereby concentrating strictly on acquisition cost and time alone. The ICERs assuming that a VAS pain score of 15 mm is achieved for all interventions are given in Table 5. The results highlight the fact that the absolute reduction in VAS pain scores does not seem to influence the rank order of preferred options. It is cost of the intervention that appears to primarily drive the model.
We also conducted a Monte Carlo simulation to determine whether, under multiple conditions of uncertainty, NJILD remained a dominant strategy. The results indicate that NJILD remains a dominant strategy that was robust across 1000 iterations of the Monte Carlo simulation. Using uniform distribution sampling across the same sensitivity ranges used in the 1-way sensitivity analyses, NJILD was favored in all 1000 iterations. These results support NJILD as the optimal strategy for analgesia during PIV cannulation.
Although a great deal of evidence has been published on the costs and effectiveness of various analgesic options for pediatric PIV cannulation, comprehensive comparison studies, allowing physicians and administrators to compare alternatives, have not been published. Decision analysis affords a method for simultaneously examining the costs and benefits of alternative clinical strategies and exploring the impact of varying key probabilities, costs, and outcomes. Our analysis suggests that the current best options include NJILD and buffered lidocaine. Their low unit cost combined with relative reduction in pain scores compared with placebo make them an attractive option for use in pediatrics.
To explore the sensitivity of our results to key variables, we conducted sensitivity and Monte Carlo analyses varying certain variables within reasonable ranges and found that our results were fundamentally unaltered. This process allowed us to determine the thresholds that could make our model applicable to other institutions with somewhat different costs, productivity, and PIV cannulation success rates.
Our analysis also provides important insight regarding costs and pain reduction that must be exhibited by new approaches to pediatric PIV cannulation pain management to be relatively cost-effective. Although other pain management approaches yielded better outcomes than the NJILD or buffered lidocaine injection (eg, iontophoresis, the lidocaine-tetracaine patch, and laser or ultrasonic preparation of the skin followed by topical lidocaine, 4%, had lower mean VAS pain scores), their unit costs made them less attractive. With the benchmark ICER of the NJILD at 1.89 (cost of $3.90; VAS pain score reduction of 2.05 cm), newer approaches will need to either have a cost less than $3.90 per patient coupled with similar pain score reductions or provide a greater than 2.05-cm reduction in VAS scores with similar unit costs.
Our analysis suggests that the most cost-effective alternative is the NJILD, yielding a 2.05-cm reduction in VAS pain score for $3.90. Alternatively, is the pain invoked with PIV cannulation worth spending $11.80? In that case, lidocaine iontophoresis might be considered, reducing the pain scores by 4.07 cm. Although our analysis provides information on which pain management modalities are on the cost-effective frontier and which alternatives are the most cost-effective, it cannot tell us how much we should be willing to spend. This is clearly an institutional and societal policy issue that must be considered in light of patient preferences, the ability to achieve clinically meaningful improvements in outcomes, and the relative cost-effectiveness of next-best alternatives.
Our study has a number of important limitations that should be considered when interpreting our results. Several studies included in this analysis were not ED based. However, we believe that pain associated with PIV cannulation in children will be similar across various hospital-based settings.
Our study also relies on self-reported VAS scores, PIV cannulation establishment times, and cannulation success rates across somewhat heterogeneous pediatric populations and physicians, with potentially varying levels of experience. Younger children, especially those aged 3 to 4 years, may rate the pain of procedures somewhat higher than their older counterparts. They also frequently show a different response when using continuous scales and select the extreme ends while neglecting the midportions of scales.61 The study that cited relatively lower weighted mean VAS scores with NJILD included children between 7 and 19 years of age. This was in contrast to studies that used EMLA, lidocaine, or buffered lidocaine and included children as young as 4 to 5 years. This approach could potentially favor NJILD during calculation of the effectiveness of analgesia. Of the 18 trials in our model, 6 included patients who were 3 to 7 years in whom the self-reported VAS score had not been validated. However, the mean age of the patients in these studies was older than 7 years. To elucidate this, we have included a summary of the age range and means reported in these 8 studies (Table 6).
Our decision analysis required some simplifying assumptions. For example, we assumed that after 1 failed attempt, intravenous cannula insertion would be successful at the next attempt at another site using conventional protocols aided by local anesthesia. This assumption was based on 90% to 91% success rates reported with the second attempt using buffered lidocaine or placebo.26 In addition, payoffs (pain scores and costs) after a failed initial attempt were considered additive across the 2 attempted intravenous cannula insertions. This is clearly a simplification that may not be true for all patients.
Furthermore, our study assumes that the local adverse effects of various modalities, other than an intolerability rate with lidocaine iontophoresis and bandage removal pain associated with EMLA, are minor and that there were no differences in the relative discomfort associated with the various modalities. Other topical agents have been known to cause minor erythema or transient cutaneous reactions. However, specific evidence to support nonparticipation or withdrawal of patients from clinical trials associated with their use was lacking. Therefore, our approach implicitly assumed that these minor reactions were included in the global self-reported pain score.
Several studies included in this analysis were not ED based. However, we believe that pain associated with PIV cannulation in children would be similar across various hospital-based settings.
We excluded analgesic agents that are not available in the United States, such as amethocaine, from our model. Given the obvious difficulties of acquiring costs of these agents, personnel costs, and hospital accounting data, combined with foreign currency fluctuations, we believe that making this more international is beyond the scope of the current study.
Finally, we relied on data from a pilot study in our ED to estimate average time to establish PIV cannulation. Although these data are not derived from multicenter trials, they are consistent with prior data.30,62
In summary, given the current data on costs and effectiveness profiles of available pain management modalities, the NJILD and injection of buffered lidocaine appear to be the preferred initial local anesthetic strategy for PIV cannulation in children. Low-dose lidocaine iontophoresis represents a third cost-effective option, although its total price of $11.80 (agent plus associated ED time) may be higher than some are willing to pay for a relatively modest incremental reduction in pain compared with the next best alternative (NJILD).
Correspondence: Jay Pershad, MD, Division of Emergency Medicine, Department of Pediatrics, Le Bonheur Children's Medical Center, 50 N Dunlap St, Memphis, TN 38103 (firstname.lastname@example.org).
Accepted for Publication: January 10, 2008.
Author Contributions:Study concept and design: Pershad and Waters. Acquisition of data: Pershad, Steinberg, and Waters. Analysis and interpretation of data: Pershad, Steinberg, and Waters. Drafting of the manuscript: Pershad, Steinberg, and Waters. Critical revision of the manuscript for important intellectual content: Pershad, Steinberg, and Waters. Statistical analysis: Steinberg and Waters. Administrative, technical, and material support: Steinberg and Waters. Study supervision: Pershad and Waters.
Financial Disclosure: None reported.
Additional Contributions: Ed Mell, MBA, director of finance at Le Bonheur Children's Medical Center, kindly assisted with this project.
Pershad J, Steinberg SC, Waters TM. Cost-effectiveness Analysis of Anesthetic Agents During Peripheral Intravenous Cannulation in the Pediatric Emergency Department. Arch Pediatr Adolesc Med. 2008;162(10):952–961. doi:10.1001/archpedi.162.10.952
Coronavirus Resource Center
Create a personal account or sign in to: